Nantahala Capital Management LLC Purchases 50,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Nantahala Capital Management LLC boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,669,943 shares of the company’s stock after acquiring an additional 50,000 shares during the period. Amneal Pharmaceuticals accounts for approximately 1.0% of Nantahala Capital Management LLC’s portfolio, making the stock its 13th largest holding. Nantahala Capital Management LLC’s holdings in Amneal Pharmaceuticals were worth $16,954,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth $26,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $42,000. Atlanta Consulting Group Advisors LLC bought a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at about $61,000. nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter worth about $62,000. Finally, Trexquant Investment LP bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $65,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 1.6 %

AMRX opened at $8.32 on Tuesday. The company has a market cap of $2.57 billion, a P/E ratio of -14.86 and a beta of 1.18. Amneal Pharmaceuticals, Inc. has a 12 month low of $3.36 and a 12 month high of $8.90. The business’s 50-day moving average price is $8.06 and its 200-day moving average price is $7.01. The company has a current ratio of 1.33, a quick ratio of 0.82 and a debt-to-equity ratio of 121.31.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. The business had revenue of $701.78 million during the quarter, compared to analysts’ expectations of $657.43 million. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. On average, equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Truist Financial upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a research report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.